CN1038473C - 草乌甲素口服剂型 - Google Patents
草乌甲素口服剂型 Download PDFInfo
- Publication number
- CN1038473C CN1038473C CN93119545A CN93119545A CN1038473C CN 1038473 C CN1038473 C CN 1038473C CN 93119545 A CN93119545 A CN 93119545A CN 93119545 A CN93119545 A CN 93119545A CN 1038473 C CN1038473 C CN 1038473C
- Authority
- CN
- China
- Prior art keywords
- dosage form
- bulleyaconitine
- peroral dosage
- form according
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- YRECILNLFWZVRM-XTNYDWJGSA-N bulleyaconitine a Chemical compound O=C([C@H]1[C@]2(O)C[C@H]3[C@]45[C@H](OC)CC[C@@]6(COC)CN([C@@H]5[C@H]([C@H](OC)[C@H]64)[C@](C[C@@H]2OC)(OC(C)=O)[C@H]31)CC)C1=CC=C(OC)C=C1 YRECILNLFWZVRM-XTNYDWJGSA-N 0.000 title claims abstract description 30
- 238000002360 preparation method Methods 0.000 title description 2
- 239000002552 dosage form Substances 0.000 claims abstract description 14
- 239000002775 capsule Substances 0.000 claims abstract description 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 4
- 239000004480 active ingredient Substances 0.000 claims abstract 3
- 229920002472 Starch Polymers 0.000 claims description 12
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 12
- 235000019698 starch Nutrition 0.000 claims description 12
- 239000008107 starch Substances 0.000 claims description 12
- 235000010489 acacia gum Nutrition 0.000 claims description 10
- 239000001785 acacia senegal l. willd gum Substances 0.000 claims description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 9
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 8
- 235000019359 magnesium stearate Nutrition 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 4
- 229920001353 Dextrin Polymers 0.000 claims description 4
- 239000004375 Dextrin Substances 0.000 claims description 4
- 239000011230 binding agent Substances 0.000 claims description 4
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 235000019425 dextrin Nutrition 0.000 claims description 4
- 239000000945 filler Substances 0.000 claims description 4
- 239000000314 lubricant Substances 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 4
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims description 4
- 239000000080 wetting agent Substances 0.000 claims description 4
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 2
- 229920002261 Corn starch Polymers 0.000 claims description 2
- 108010010803 Gelatin Proteins 0.000 claims description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 2
- MXRIRQGCELJRSN-UHFFFAOYSA-N O.O.O.[Al] Chemical compound O.O.O.[Al] MXRIRQGCELJRSN-UHFFFAOYSA-N 0.000 claims description 2
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 2
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims description 2
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 claims description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 2
- 239000008120 corn starch Substances 0.000 claims description 2
- 235000019700 dicalcium phosphate Nutrition 0.000 claims description 2
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims description 2
- 239000012153 distilled water Substances 0.000 claims description 2
- 239000000499 gel Substances 0.000 claims description 2
- 239000008273 gelatin Substances 0.000 claims description 2
- 229920000159 gelatin Polymers 0.000 claims description 2
- 235000019322 gelatine Nutrition 0.000 claims description 2
- 235000011852 gelatine desserts Nutrition 0.000 claims description 2
- 239000008101 lactose Substances 0.000 claims description 2
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 claims description 2
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 claims description 2
- 239000001095 magnesium carbonate Substances 0.000 claims description 2
- 229910000021 magnesium carbonate Inorganic materials 0.000 claims description 2
- 239000000395 magnesium oxide Substances 0.000 claims description 2
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 claims description 2
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 claims description 2
- NALMPLUMOWIVJC-UHFFFAOYSA-N n,n,4-trimethylbenzeneamine oxide Chemical compound CC1=CC=C([N+](C)(C)[O-])C=C1 NALMPLUMOWIVJC-UHFFFAOYSA-N 0.000 claims description 2
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 claims description 2
- 239000012188 paraffin wax Substances 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 2
- 229920000053 polysorbate 80 Polymers 0.000 claims description 2
- 239000002002 slurry Substances 0.000 claims description 2
- 239000011697 sodium iodate Substances 0.000 claims description 2
- 229940032753 sodium iodate Drugs 0.000 claims description 2
- 235000015281 sodium iodate Nutrition 0.000 claims description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 2
- 239000006188 syrup Substances 0.000 claims description 2
- 235000020357 syrup Nutrition 0.000 claims description 2
- 238000006243 chemical reaction Methods 0.000 description 11
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 11
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 10
- 241000700159 Rattus Species 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 9
- 208000002193 Pain Diseases 0.000 description 8
- 230000037396 body weight Effects 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 230000036407 pain Effects 0.000 description 8
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 7
- 229960005181 morphine Drugs 0.000 description 6
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 6
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 6
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- 230000036592 analgesia Effects 0.000 description 4
- 230000000202 analgesic effect Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 239000002510 pyrogen Substances 0.000 description 4
- 229920001817 Agar Polymers 0.000 description 3
- 231100000111 LD50 Toxicity 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 238000007689 inspection Methods 0.000 description 3
- 238000012417 linear regression Methods 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 239000002547 new drug Substances 0.000 description 3
- 238000005057 refrigeration Methods 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 102000002322 Egg Proteins Human genes 0.000 description 2
- 108010000912 Egg Proteins Proteins 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 238000012449 Kunming mouse Methods 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000283977 Oryctolagus Species 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000036760 body temperature Effects 0.000 description 2
- 230000004856 capillary permeability Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000007891 compressed tablet Substances 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 229940126701 oral medication Drugs 0.000 description 2
- 210000004681 ovum Anatomy 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 241000701413 Aconitum kusnezoffii Species 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- -1 Dichlorodiphenyl Acetate Chemical compound 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- 206010022061 Injection site erythema Diseases 0.000 description 1
- 241000412609 Morphina Species 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 241000233855 Orchidaceae Species 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 206010034464 Periarthritis Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 239000006053 animal diet Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 229960000935 dehydrated alcohol Drugs 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 229960004756 ethanol Drugs 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 238000009592 kidney function test Methods 0.000 description 1
- 238000011005 laboratory method Methods 0.000 description 1
- 229960005195 morphine hydrochloride Drugs 0.000 description 1
- XELXKCKNPPSFNN-BJWPBXOKSA-N morphine hydrochloride trihydrate Chemical compound O.O.O.Cl.O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O XELXKCKNPPSFNN-BJWPBXOKSA-N 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 239000007779 soft material Substances 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 230000004206 stomach function Effects 0.000 description 1
- 231100000456 subacute toxicity Toxicity 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
批号日期项目 | 920211 | 920213 | 920216 | 规定指标 | |||
92年2月 | 92年5月 | 92年2月 | 92年5月 | 92年2月 | 92年5月 | ||
性状 | 符合规定 | 符合规定 | 符合规定 | 符合规定 | 符合规定 | 符合规定 | 白色压制片 |
鉴别(1) | 符合规定 | 符合规定 | 符合规定 | 符合规定 | 符合规定 | 符合规定 | 261±1有最大吸收 |
鉴别(2) | 正反应 | 正反应 | 正反应 | 反应 | 正反应 | 正反应 | 应为正反应 |
崩解时限 | 1分钟 | 1分钟 | 2分钟 | 2分钟 | 2分钟 | 2分钟 | 15分钟内崩解 |
重量差异 | 符合规定 | 符合规定 | 符合规定 | 符合规定 | 符合规定 | 符合规定 | 应符合规定 |
细菌数 | 70个 | 60个 | 62个 | 1000个 | |||
霉菌数 | 20个 | 30个 | 28个 | 100个 | |||
大肠杆菌 | 未检出 | 未检出 | 未检出 | 未检出 |
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN93119545A CN1038473C (zh) | 1993-10-23 | 1993-10-23 | 草乌甲素口服剂型 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN93119545A CN1038473C (zh) | 1993-10-23 | 1993-10-23 | 草乌甲素口服剂型 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1107697A CN1107697A (zh) | 1995-09-06 |
CN1038473C true CN1038473C (zh) | 1998-05-27 |
Family
ID=4992990
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN93119545A Expired - Lifetime CN1038473C (zh) | 1993-10-23 | 1993-10-23 | 草乌甲素口服剂型 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1038473C (zh) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1069519C (zh) * | 1998-03-17 | 2001-08-15 | 昆明制药股份有限公司 | 草乌甲素软胶囊及其生产方法 |
CN100518721C (zh) * | 2006-08-08 | 2009-07-29 | 云南昊邦制药有限公司 | 一种含有乌头碱的肠溶速释片及其制备方法 |
CN102727492A (zh) * | 2012-07-23 | 2012-10-17 | 云南昊邦制药有限公司 | 一种具有镇痛消炎作用的复方制剂 |
CN102940614B (zh) * | 2012-12-14 | 2014-01-08 | 云南昊邦制药有限公司 | 一种含草乌甲素的片剂制剂方法 |
CN105997949B (zh) * | 2016-06-02 | 2019-04-09 | 云南省药物研究所 | 一种草乌甲素口腔分散膜制剂及其制备工艺 |
CN105853469A (zh) * | 2016-06-12 | 2016-08-17 | 韩春超 | 一种灵芝镇痛胶囊制剂及其制备方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1054976A (zh) * | 1991-03-21 | 1991-10-02 | 云南大学 | 草乌甲素及其类似生物碱制备 |
-
1993
- 1993-10-23 CN CN93119545A patent/CN1038473C/zh not_active Expired - Lifetime
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1054976A (zh) * | 1991-03-21 | 1991-10-02 | 云南大学 | 草乌甲素及其类似生物碱制备 |
Non-Patent Citations (1)
Title |
---|
药学学报21(12) 1986.12.1 草鸟甲素的镇痛作用及生理依赖性研究 * |
Also Published As
Publication number | Publication date |
---|---|
CN1107697A (zh) | 1995-09-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3666267B1 (en) | Combination product containing a limonoid compound and metformin | |
CN101073563B (zh) | 一种含有右旋布洛芬和左旋西替利嗪的手性组合物及其缓速释双层片 | |
CN1038473C (zh) | 草乌甲素口服剂型 | |
CN1586475A (zh) | 维生素c口腔崩解片及其制备方法 | |
CN103751201A (zh) | 一种犬、猫用抗寄生虫口服崩解片及其制备方法 | |
CN1833661A (zh) | 螺旋藻咀嚼片及其制备方法 | |
CN1316978C (zh) | 复方硫酸氨基葡萄糖分散片制剂及其制备方法 | |
US20070269512A1 (en) | Gastroretentive sustained release formulations | |
CN1634013A (zh) | 葡萄糖酸锌口腔崩解片及其制备工艺 | |
CN1887312A (zh) | 一种中药组合物及其制备方法和质量控制方法 | |
CN1476898A (zh) | 口服给药后能延长释放的治疗感冒复方骨架片 | |
CN1903351A (zh) | 妇宁凝胶剂及其制备方法 | |
DE102012102414A1 (de) | Pharmazeutische Zusammensetzung für die einmal tägliche Anwendung antidiabetischer Arzneimittel wie Metformin mit Zwei-Puls-Freisetzung | |
CN1742726A (zh) | 阿魏酸哌嗪口腔崩解片及其制备方法 | |
CN106955273B (zh) | 一种含有钠-葡萄糖协同转运蛋白2抑制剂的药物组合物 | |
CN1732911A (zh) | 琥珀酸亚铁缓释制剂及其制备方法 | |
CN1080855A (zh) | 维生素矿物质防癌复方 | |
CN1287801C (zh) | 治疗前列腺炎的药物组合物 | |
CN1810237A (zh) | 一种氨溴索盐类缓释片及其制备方法 | |
CN1224390C (zh) | 含吡咯并喹啉醌的治疗和预防脂肪肝的药物组合物 | |
CN1621044A (zh) | 一种预防和治疗关节炎的组合物、含有该组合物制剂及其制备工艺和用途 | |
CN1634073A (zh) | 左氧氟沙星或其药用盐的口腔崩解片 | |
CN100346780C (zh) | 一种预防和治疗肥胖症的复方制剂及其制备方法 | |
CN110090213B (zh) | 过渡金属螯合的叶绿素衍生物改善耳微循环障碍的用途 | |
CN1209109C (zh) | 阿昔莫司缓释片 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee |
Owner name: YUNNAN BIOLOGY VALLEY MILEI PHARMACEUTICAL CO., LT Free format text: FORMER NAME OR ADDRESS: PHARMACEUTICAL FACTORY, MILE COUNTY, YUNNAN PROV. |
|
CP01 | Change in the name or title of a patent holder |
Patentee after: Yunnan biological Valley Maitreya Pharmaceutical Co., Ltd. Patentee before: Pharmaceutical Factory, Mile County, Yunnan Prov. |
|
ASS | Succession or assignment of patent right |
Owner name: YUNNAN PROV HAOBANG PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: YUNNAN BIOLOGY VALLEY MILEI PHARMACEUTICAL CO., LTD. Effective date: 20051209 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20051209 Address after: 16, building 650021, Ruyi building, Renmin Middle Road, Kunming, Yunnan Patentee after: Haobang Pharmaceutical Co., Ltd., Yunnan Address before: 652300 Maitreya County of Yunnan province ran Weng Lu No. 8 Patentee before: Yunnan biological Valley Maitreya Pharmaceutical Co., Ltd. |
|
C17 | Cessation of patent right | ||
CX01 | Expiry of patent term |
Expiration termination date: 20131023 Granted publication date: 19980527 |